Long-term Survival, Tolerability, and Safety of First-Line Bevacizumab and FOLFIRI in Combination With Ginsenoside-Modified Nanostructured Lipid Carrier Containing Curcumin in Patients With Unresectable Metastatic Colorectal Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeon, Youngbae | - |
dc.contributor.author | Sym, Sun Jin | - |
dc.contributor.author | Yoo, Bong Kyu | - |
dc.contributor.author | Baek, Jeong-Heum | - |
dc.date.accessioned | 2022-07-19T02:40:53Z | - |
dc.date.available | 2022-07-19T02:40:53Z | - |
dc.date.created | 2022-07-19 | - |
dc.date.issued | 2022-06 | - |
dc.identifier.issn | 1534-7354 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/85020 | - |
dc.description.abstract | Background: Colorectal cancer is the third most common malignant disease and the second leading cause of death worldwide. Previous studies showed improved bioavailability and cytotoxicity of ginsenoside-modified nanostructured lipid carrier containing curcumin (G-NLC) in human colon cancer cell lines. This study aimed to evaluate the safety and tolerability with long-term survival rates in patients with colorectal cancer with unresectable metastases after treatment with first-line bevacizumab/FOLFIRI (folinic acid, bolus/continuous fluorouracil, and irinotecan) in combination with a dietary supplement of G-NLC. Methods: This study was a prospective, observational, single-group analysis. The enrolled patients had colorectal cancer with unresectable metastases and were administered bevacizumab and FOLFIRI in combination with daily oral G-NLC as first-line treatment. Overall survival, progression-free survival, tumor response, and adverse events were evaluated. Results: A total of 44 patients were enrolled between 2015 and 2019. The median age was 65 (range 45-81) years and the sex ratio was 31:13 (male:female). The primary tumor locations were the colon (31 patients) and rectum (13 patients). The metastatic sites included, liver only (n = 20), lung only (n = 6), both liver and lung (n = 12), and others (n = 6). The median duration of curcumin supply was 7.9 (range 0.9-16.6) months. The most common grade 3 or higher adverse events were neutropenia (n = 15, 34.1%), followed by nausea (n = 4, 9.1%) and vomiting (n = 4, 9.1%). Within the median follow-up period of 22.8 months, the median overall survival was 30.7 months, and the median progression-free survival was 12.8 months. None of the patients achieved complete response (CR); however, 9 patients showed partial response (PR), and 3 patients underwent conversion surgery. Conclusions: Bevacizumab/FOLFIRI with G-NLC as first-line chemotherapy in patients with colorectal cancer with unresectable metastases presented comparable long-term survival outcomes with acceptable toxicity outcomes. Additional randomized controlled studies are needed to establish definitive conclusions regarding this new regimen for metastatic colorectal cancer. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS INC | - |
dc.relation.isPartOf | INTEGRATIVE CANCER THERAPIES | - |
dc.title | Long-term Survival, Tolerability, and Safety of First-Line Bevacizumab and FOLFIRI in Combination With Ginsenoside-Modified Nanostructured Lipid Carrier Containing Curcumin in Patients With Unresectable Metastatic Colorectal Cancer | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000813691700001 | - |
dc.identifier.doi | 10.1177/15347354221105498 | - |
dc.identifier.bibliographicCitation | INTEGRATIVE CANCER THERAPIES, v.21 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85131849492 | - |
dc.citation.title | INTEGRATIVE CANCER THERAPIES | - |
dc.citation.volume | 21 | - |
dc.contributor.affiliatedAuthor | Jeon, Youngbae | - |
dc.contributor.affiliatedAuthor | Sym, Sun Jin | - |
dc.contributor.affiliatedAuthor | Yoo, Bong Kyu | - |
dc.contributor.affiliatedAuthor | Baek, Jeong-Heum | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | curcumin | - |
dc.subject.keywordAuthor | metastatic colorectal cancer | - |
dc.subject.keywordAuthor | chemotherapy | - |
dc.subject.keywordAuthor | survival | - |
dc.subject.keywordAuthor | adverse event | - |
dc.subject.keywordPlus | PHYSICOCHEMICAL PROPERTIES | - |
dc.subject.keywordPlus | NANOPARTICLE DISPERSION | - |
dc.subject.keywordPlus | RANDOMIZED-TRIALS | - |
dc.subject.keywordPlus | PLUS BEVACIZUMAB | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | TUMORS | - |
dc.subject.keywordPlus | BIOAVAILABILITY | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | CETUXIMAB | - |
dc.subject.keywordPlus | RESECTION | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Integrative & Complementary Medicine | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Integrative & Complementary Medicine | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.